by Plus Therapeutics | Jul 16, 2025 | GBM
Today marks GBM Awareness Day, an important opportunity to raise awareness about glioblastoma (GBM)—an aggressive and life-threatening brain cancer that continues to pose significant challenges for patients, families, and clinicians worldwide. At Plus Therapeutics, we...
by Plus Therapeutics | Jul 15, 2025 | LM
Plus Therapeutics is pleased to announce its participation in the upcoming Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference, taking place August 14–16, 2025, at the Baltimore Waterfront Marriott Hotel in...
by Plus Therapeutics | Jul 8, 2025 | LM
Plus Therapeutics is pleased to announce that the first patients have been treated in the ReSPECT-LM dose optimization clinical trial, evaluating REYOBIQ™ (rhenium Re 186 obisbemeda) for the treatment of leptomeningeal metastases (LM)—a devastating and often...
by Plus Therapeutics | Jun 30, 2025 | LM
Plus Therapeutics is pleased to announce the initiation of the ReSPECT-LM dose optimization clinical trial for REYOBIQ™ (rhenium Re 186 obisbemeda), a radiotherapeutic designed to target and treat leptomeningeal metastases (LM)—a devastating complication of metastatic...
by Plus Therapeutics | Jun 30, 2025 | Uncategorized
Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care At Plus Therapeutics, our mission is clear: to address some of the toughest challenges in oncology by improving the efficacy, precision, and convenience of modern radiotherapeutic treatments....
Recent Comments